Jennifer Gershman, PharmD, CPh
Jennifer Gershman, PharmD, CPh, received her PharmD degree from Nova Southeastern University (NSU) College of Pharmacy in 2006 and completed a 2-year drug information residency. She served as a pharmacy professor at NSUâ€™s College of Pharmacy for 6 years, managed the drug information center, and conducted medication therapy management reviews. Dr. Gershman has published research on prescription drug abuse, regulatory issues, and drug information in various scholarly journals. Additionally, she received the Sheriffâ€™s Special Recognition Award for her collaboration with the Broward, Florida Sheriffâ€™s Office to prevent prescription drug abuse through a drug disposal program. She has also presented at pharmacist and physician continuing education programs on topics that include medication errors, prescription drug abuse, and legal and regulatory issues. Dr. Gershman can be followed on Twitter @jgershman2
Pediatric Flu Deaths
Approximately half of the pediatric deaths occurred in children with a medical condition that placed them at high risk of developing serious flu-related complications.1 About 60% of these children died after hospital admission, and approximately 40% died at home or the emergency department. Additionally, most children died within 7 days of symptom onset. The influenza vaccine is recommended for everyone 6 months and older, and children younger than 5 years (especially younger than 2 years) are at an increased risk of flu-related complications.1
Intranasal Flu Vaccine Recommendations for 2018-2019 Season
The CDC’s Advisory Committee on Immunization Practices has recommended the option of using the intranasal live attenuated influenza vaccine (LAIV4) for the 2018-2019 flu season.3 The LAIV4 was not recommended during the previous two flu seasons due to its lack of efficacy. The manufacturer claims that the LAIV4 FluMist has been reformulated, and the CDC will continue to monitor its efficacy in the upcoming flu season. However, the American Academy of Pediatrics (AAP) recommends the inactivated influenza vaccine as the primary choice for all children due to the lack of efficacy of the LAIV4 in previous flu seasons and unknown effectiveness for the upcoming season. The AAP recommends that the LAIV4 can be offered to children that would not otherwise receive a flu vaccine, which may be an option for vaccine hesitant families. Children younger than 2 years of age cannot receive the LAIV4.3
Pharmacist’s Role in the Upcoming Season
Pharmacists play an important role in flu prevention through vaccination and education. With expanding state laws, pharmacists have the authority to vaccinate children in some states.4 With pharmacists being so accessible, this can ultimately lead to increased influenza vaccine rates among the pediatric population. Pharmacists can also clear up common misconceptions regarding the flu vaccine. Patients should be educated that it takes about 2 weeks for the influenza vaccine to become effective once it is administered. The CDC recommends that individuals receive the flu vaccine once it becomes available, especially by the end of October as it is unpredictable when the season will begin. Pharmacists should continue to recommend the influenza vaccine to pregnant patients as this can pass protective antibodies to their babies. Patient education over the summer months can help prepare the community for the upcoming flu season.
- Centers for Disease Control and Prevention. CDC reported flu deaths in children exceeds seasonal high. https://www.cdc.gov/flu/spotlights/reported-flu-children-deaths.htm. Accessed June 11, 2018.
- Shang M, Blanton L, Brammer L, et al. Influenza-associated pediatric deaths in the United States, 2010-2016. Pediatrics. 2018;141(4): doi:10.1542/peds.2017-2918.
- American Academy of Pediatrics. AAP influenza immunization recommendations revised for 2018-’19 season. http://www.aappublications.org/news/2018/06/07/influenza060718. Accessed June 11, 2018.
- Schmit CD, Penn MS. Expanding state laws and a growing role for pharmacists in vaccination services. J Am Pharm Assoc. 2017;57(6):661-669.